AstraZeneca Pharma India to launch Enhertu in January 2024
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer
Lacosamide is indicated to treat partial-onset seizures
10+ emerging markets, Japan & ANZ transition in final phase
Laurus Synthesis receives Form 483 with 5 observations from USFDA
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
Receives registration of Valganciclovir powder for oral solution in Germany
Expands patient reach to remotest towns by furthering investment in GoApptiv
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
Pantoprazole Sodium Delayed-Release Tablets are indicated for short-term treatment of Erosive Esophagitis associated with GERD
Subscribe To Our Newsletter & Stay Updated